Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KMT5A | Q9NQR1 | 7/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
| ▸ | PGK1 | P00558 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816277 | 0.94 | PGK1 (0.50) | KDM4ETDP1KMT5APGK1MEN1 | |
| SCHEMBL14027625 | 0.91 | PGK1 (0.43) | KDM4ETDP1KMT5APGK1 | |
| SCHEMBL14027641 | 0.84 | KDM4E (0.50) | KDM4ETDP1KMT5APGK1NPSR1 | |
| SCHEMBL4820885 | 0.84 | ACP1 (0.45) | KDM4EMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4908228 | 0.83 | SLC2A1 (0.45) | KDM4EPGK1MEN1KMT2ALMNA | |
| SCHEMBL4825375 | 0.82 | SYK (0.40) | KDM4EKMT5AMEN1KMT2ALMNA | |
| SCHEMBL4814121 | 0.80 | FLT3 (0.39) | KDM4EKMT5ATOP2AMEN1KMT2A | |
| SCHEMBL4821889 | 0.80 | KDM1A (0.45) | KMT5ATOP2AKMT2A | |
| SCHEMBL14027619 | 0.79 | TOP2A (0.46) | KDM4EKMT5ATOP2AKMT2ALMNA | |
| SCHEMBL14027631 | 0.78 | MC4R (0.37) | KDM4ETDP1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | KDM4E 1351/4885TDP1 4856/4885KMT5A 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.